| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3199952 | Journal of Allergy and Clinical Immunology | 2010 | 20 Pages |
Abstract
Population-based asthma screening is not cost-effective at $50,000 per QALY and has only a 20% chance of being cost-effective at $100,000 per QALY. The most efficient approach is to screen for previously diagnosed but poorly controlled asthma. Linking screening with better treatment, and long-term adherence strategies might yield future cost-effective approaches.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Joe K. MD, PhD, Roni MD, William C. MD, Lynn B. MSPH, PhD,